Agilent Introduces New Column Innovations for Biotherapeutics Development
Complete the form below to unlock access to ALL audio articles.
Agilent Technologies Inc. has introduced the AdvanceBio RP-mAb, a reversed-phase column optimized to separate monoclonal antibodies. The AdvanceBio RP-mAb-the latest in a series of products in the AdvanceBio family-is part of Agilent's extensive R&D effort to support biological research and drug development by increasing the accuracy and productivity of biocolumns technology.
Monoclonal antibodies, or mAbs, are the primary proteins researchers study to develop biotherapeutics, biosimilars and biobetters.
"The Agilent AdvanceBio RP-mAb is the only reversed-phase column optimized specifically for mAbs," said Anne Jones, Agilent's vice president of Chemistries. "Its 450Å pore size is optimal for obtaining higher resolution-a vital factor for researchers, as mAbs are notoriously difficult to analyze."
Like all Agilent's industry-leading AdvanceBio products, the new column is designed and manufactured solely by Agilent for premium, end-to-end quality control.
AdvanceBio RP-mAb columns leverage Agilent's Poroshell technology for fast, high-resolution analysis of intact mAbs. The column is 3.5 μm, 450Å superficially porous, and stable to 600 bar. Agilent also offers three chemistries-C8, C4 and unique diphenyl-providing researchers with options for refining their separations.
